Streetbeat News

Products Services

AAPL

Tech analyst Ming-Chi Kuo has suggested that Apple Inc. (NASDAQ:AAPL) may incorporate a new technology, Resin Coated Copper (RCC), for the mainboard of the iPhone 17, potentially offering enhanced internal space and cost-saving benefits. However, this technology won't be adopted for the iPhone 16 due to concerns about its fragility. Ajinomoto is currently the leading supplier of RCC material.

Portfolio Pulse from Ananya Gairola

October 13, 2023 | 2:00 am

JAPAY

NFLX

PM

Netflix's new docuseries 'Big Vape: The Rise and Fall of Juul' tells the story of how e-cigarette startup Juul, once valued at nearly $40 billion, crashed due to aggressive marketing to teens and millennials that led to the vaping crisis. The series also highlights the role of Japan Tobacco International (JAPAY) and Philip Morris (PM) in the rise of Juul.

Portfolio Pulse from Maureen Meehan

October 13, 2023 | 12:29 am

BTCUSD

PARA

PARAA

South Park, a long-running animated comedy, is set to take on the topic of artificial intelligence in its 2023 season. This follows the show's 2022 focus on cryptocurrency. The upcoming streaming special, 'South Park: Joining the Panderverse', will air on Paramount Global's streaming platform, Paramount+. The show's creators, Matt Stone and Trey Parker, signed a deal with Paramount in 2021 for six more seasons and 14 movies.

Portfolio Pulse from Chris Katje

October 12, 2023 | 10:57 pm

BA

SPR

Boeing (BA) and Spirit AeroSystems (SPR) have expanded the scope of inspections for the 737 Max aft pressure bulkhead. This move is part of their ongoing efforts to ensure the safety and reliability of the aircraft.

Portfolio Pulse from Charles Gross

October 12, 2023 | 9:43 pm

LUXH

LuxUrban Hotels has announced the opening of three new hotels in New York City, with plans to add more than 1,600 rooms to its portfolio by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 9:38 pm

NVTA

Invitae (NYSE:NVTA), a medical genetics company, announced the results of a study on universal hereditary cancer genetic testing in breast cancer patients. The study, conducted with The Outer Banks Hospital in North Carolina, found that universal genetic testing improves patient outcomes and may reduce treatment costs. The study also found that 91.4% of patients underwent testing and received results that could aid in their healthcare journey.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:43 pm

PANL

Pangaea Logistics Solutions Ltd. (NASDAQ:PANL) announced that its dry bulk carrier, Nordic Nuluujaak, has been awarded the Class Silent (E) Notation by DNV, making it the first dry bulk carrier to receive this certification. The Silent (E) Notation is given to vessels that can effectively reduce environmental noise emissions. The company's CEO, Mark Filanowski, emphasized the importance of reducing ecological impact, including underwater noise.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:41 pm

CLLS

Cellectis and Imagine Institute have published a proof-of-concept study of a gene surgery candidate to treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1). The preclinical results demonstrated that the PIK3CD gene can be efficiently corrected by TALEN®-mediated gene insertion, rescuing PI3K signaling and normalizing the transcriptomic status of APDS1 patient CD8+ T-cells.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:38 pm

SGHT

Sight Sciences, Inc. (NASDAQ:SGHT) has announced the full phase I results from the SAHARA randomized controlled trial, demonstrating that TearCare technology was superior to Restasis prescription eyedrops for the treatment of dry eye disease. The study included 345 subjects at 25 sites in 14 states. The results are expected to be published in a peer-reviewed journal in late 2023.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:37 pm

IMRX

Immuneering Corporation (NASDAQ:IMRX) presented encouraging preclinical data for IMM-1-104 and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The data demonstrated high sensitivity in a wide range of MAPK-driven tumor types, including models of RAS and RAF mutant melanoma, pancreatic cancer, and lung cancer. The company believes that IMM-1-104 and IMM-6-415, alone, and in combination with other agents, have the potential to bring significant benefit to broad populations of patients with RAS or RAF mutant cancers.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 8:36 pm